Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Carcinoma, Intraductal, Noninfiltrating 6Neoplasms 4Neoplasm Metastasis 3Breast Neoplasms, Male 3Breast Diseases 3Breast Carcinoma In Situ 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Sexual Dysfunction, Physiological 1Seizures 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Lethal Congenital Contracture Syndrome 2 1Inflammatory Breast Neoplasms 1Hypogonadism 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Epilepsy 1Endometrial Stromal Tumors 1ER+ Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasm Female 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Carcinoma × Anastrozole × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡